Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences Stock Forecast

Stock Price Forecast

The 22 analysts that cover Neurocrine Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $180.91, which forecasts a 41.71% increase in the stock price over the next year. The lowest target is $140 and the highest is $242.

Price Target: $180.91 (+41.71%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$140	$180.91	$179	$242
Change	+9.67%	+41.71%	+40.22%	+89.57%

Analyst Ratings

The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	10	12	12	11	11	10
Buy	8	8	6	8	8	9
Hold	1	2	3	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	19	22	21	22	22	22

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Marc Goodman Leerink Partners	Leerink Partners	Buy Maintains $160 → $170	Buy	Maintains	$160 → $170	+33.17%	Apr 22, 2026
Jeffrey Hung Morgan Stanley	Morgan Stanley	Hold Maintains $173 → $185	Hold	Maintains	$173 → $185	+44.92%	Apr 10, 2026
Yigal Nochomovitz Citigroup	Citigroup	Strong Buy Maintains $204 → $242	Strong Buy	Maintains	$204 → $242	+89.57%	Apr 7, 2026
Sumant Kulkarni Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $164 → $200	Strong Buy	Maintains	$164 → $200	+56.67%	Apr 7, 2026
Laura Chico Wedbush	Wedbush	Buy Maintains $151 → $166	Buy	Maintains	$151 → $166	+30.03%	Apr 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

3.57B

Increased by 24.73%

from 2.86B

Revenue Next Year

4.04B

Increased by 13.14%

from 3.57B

EPS This Year

6.19

Increased by 32.58%

from 4.67

EPS Next Year

8.35

Increased by 34.81%

from 6.19

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	1.13B	1.49B	1.89B	2.36B	2.86B	3.57B	4.04B
Revenue Growth	8.38%	31.34%	26.76%	24.81%	21.45%	24.73%	13.14%
EPS	0.92	1.56	2.47	3.29	4.67	6.19	8.35
EPS Growth	-77.89%	69.57%	58.33%	33.20%	41.95%	32.58%	34.81%
Forward PE	-	-	-	-	-	20.62	15.29
No. Analysts	-	-	-	-	-	31	29

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030	2031	2032	2033
High	4.0B	5.1B
Avg	3.6B	4.0B
Low	3.2B	3.4B

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	40.2%	43.8%
Avg	24.7%	13.1%
Low	13.5%	-4.8%

EPS Forecast

EPS	2026	2027	2028	2029	2030	2031	2032	2033
High	7.57	14.81
Avg	6.19	8.35
Low	4.26	4.58

EPS Growth

EPS Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	62.1%	139.1%
Avg	32.6%	34.8%
Low	-8.7%	-26.1%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.